Mostrar el registro sencillo del ítem
dc.contributor.author | Murad, Mohammad Hassan | |
dc.contributor.author | Larrea-Mantilla, Laura | |
dc.contributor.author | Haddad, Abdullah | |
dc.contributor.author | Spencer-Bonilla, Gabriela | |
dc.contributor.author | Serrano, Valentina | |
dc.contributor.author | Rodriguez-Gutierrez, Rene | |
dc.contributor.author | Alvarez-Villalobos, Neri | |
dc.contributor.author | Benkhadra, Khaled | |
dc.contributor.author | Gionfriddo, Michael R. | |
dc.contributor.author | Prokop, Larry J. | |
dc.contributor.author | Brito, Juan P. | |
dc.contributor.author | Ponce, Oscar J. | |
dc.date.accessioned | 2019-07-04T16:59:19Z | |
dc.date.available | 2019-07-04T16:59:19Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/6722 | |
dc.description.abstract | BACKGROUND: This systematic review summarizes the benefits of treating blood pressure (BP) in individuals 65 years and older. METHODS: We included randomized trials that evaluated BP-lowering medications or BP targets in individuals 65 years and older. Trials were selected and appraised by pairs of independent reviewers. RESULTS: We included 19 trials (42,134 patients). In individuals 65 years or older, antihypertensive therapy was associated with a reduction in all-cause mortality [relative risk: 0.88 (95% CI: 0.81 to 0.94); high certainty evidence; mean follow-up 31 months], cardiovascular mortality, myocardial infarction, heart failure, stroke, and chronic kidney disease. Individuals 75 years or older had a significant reduction in the risk of all-cause and cardiovascular mortality, stroke, and heart failure. Strict systolic BP targets (<120 mm Hg and <130 mm Hg) were associated with a significant reduction in the risk of all-cause and cardiovascular mortality and heart failure, whereas more liberal systolic targets (<150 mm Hg and <160 mm Hg) were associated with lower risk of heart failure and stroke. Older adults with type 2 diabetes mellitus (DM) had lower risk of chronic kidney disease without a significant reduction in other outcomes. However, there was no significant difference in estimates (i.e., interaction) between those with and without DM. CONCLUSIONS: Individuals aged 65 years and older or 75 years and older who receive antihypertensive therapy have statistically significant reduction in the risk of all-cause and cardiovascular mortality, heart failure, and stroke. There was no statistically significant difference in estimates between those with and without DM. | en_US |
dc.language.iso | eng | |
dc.publisher | Oxford University Press | |
dc.relation.ispartofseries | Journal of Clinical Endocrinology and Metabolism | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Antihypertensive | en_US |
dc.subject | Older Adults | en_US |
dc.subject | Systematic Review | en_US |
dc.title | Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1210/jc.2019-00197 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.18 | |
dc.relation.issn | 1945-7197 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |